Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 2/20 | 0.50 |
| ▸ | DRD2 | P14416 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.50 |
| ▸ | HTR5A | P47898 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.45 |
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.43 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4832625 | 0.81 | GAA (0.43) | ALDH1A1HRH1 | |
| SCHEMBL1382851 | 0.78 | FLT1 (0.60) | CYP1A2CYP2D6HTR5AL3MBTL1HTT | |
| SCHEMBL7015751 | 0.78 | CYP1A2 (0.56) | HTR1ADRD2CYP1A2CYP2D6HTR5A | |
| SCHEMBL1382926 | 0.76 | FLT1 (0.46) | HTR1ADRD2CYP1A2CYP2D6HTR5A | |
| SCHEMBL4814640 | 0.76 | FLT1 (0.48) | CYP1A2CYP2D6HTR5ACHRNA7GPR84 | |
| SCHEMBL28480379 | 0.76 | CYP1A2 (0.53) | HTR1ADRD2CYP1A2CYP2D6CHRNA7 | |
| SCHEMBL29485692 | 0.74 | CHRNA7 (0.74) | CYP1A2CYP2D6CHRNA7CYP2A6HRH4 | |
| SCHEMBL724866 | 0.74 | CHRNA7 (0.74) | CYP1A2CYP2D6CHRNA7CYP2A6HRH4 | |
| SCHEMBL7128318 | 0.74 | MET (0.42) | CYP11B1CYP11B2 | |
| SCHEMBL3159683 | 0.73 | CYP11B1 (0.44) | CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7323474-B2 | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase | NOVARTIS AG (CH) | 2008-01-29 | — | — | US | disclosed |
| EP-1254138-B1 | PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE | NOVARTIS AG (CH) | 2005-05-11 | — | — | EP | disclosed |
| US-20040209894-A1 | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase | BOLD GUIDO | 2004-10-21 | — | — | US | disclosed |
| US-6706731-B2 | WITH ISOQUINOLINE DERIVATIVES AS ANTITUMOR AGENTS | NOVARTIS AG (CH) | 2004-03-16 | — | — | US | disclosed |
| US-20030158409-A1 | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase | NOVARTIS AG (CH) | 2003-08-21 | — | — | US | disclosed |
| EP-1254138-A1 | PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE | Novartis AG (CH) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001058899-A1 | PYRIDINE DERIVATIVES INHIBITING ANGIOGENESIS AND/OR VEGF RECEPTOR TYROSINE KINASE | NOVARTIS AG (CH) | 2001-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040209894-A1 | Pyridine derivatives inhibiting angiogenesis and/or VEGF receptor tyrosine kinase | FLT1, FLT4, KDR | HTR1A 713/4885DRD2 3784/4885CYP1A2 269/4885 |
| US-20030158409-A1 | Pyridine derivatives inhibiting angiogenesis and/or vegf receptor tyrosine kinase | FLT1, FLT4, KDR | HTR1A 922/4885DRD2 3529/4885CYP1A2 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.